Sign Up
OverviewAPI
Investors with losses in excess of $100,000 are reminded of the April 9, 2024, deadline to file lead plaintiff applications in a class action lawsuit against Amylyx Pharmaceuticals, Inc., involving allegations of failure to disclose crucial information about the commercial potential of their ALS treatment, RELYVRIO.

Ask a question